DNLI
Price
$14.30
Change
+$2.01 (+16.35%)
Updated
Apr 2, 03:02 PM (EDT)
Capitalization
1.78B
41 days until earnings call
LGND
Price
$108.73
Change
+$3.91 (+3.73%)
Updated
Apr 2, 04:59 PM (EDT)
Capitalization
2.02B
28 days until earnings call
Ad is loading...

DNLI vs LGND

Header iconDNLI vs LGND Comparison
Open Charts DNLI vs LGNDBanner chart's image
Denali Therapeutics
Price$14.30
Change+$2.01 (+16.35%)
Volume$8.9K
Capitalization1.78B
Ligand Pharmaceuticals
Price$108.73
Change+$3.91 (+3.73%)
Volume$15.6K
Capitalization2.02B
DNLI vs LGND Comparison Chart
Loading...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LGND
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
DNLI vs. LGND commentary
Apr 02, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNLI is a Buy and LGND is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 02, 2025
Stock price -- (DNLI: $12.29 vs. LGND: $104.82)
Brand notoriety: DNLI and LGND are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNLI: 248% vs. LGND: 87%
Market capitalization -- DNLI: $1.78B vs. LGND: $2.02B
DNLI [@Biotechnology] is valued at $1.78B. LGND’s [@Biotechnology] market capitalization is $2.02B. The market cap for tickers in the [@Biotechnology] industry ranges from $302.51B to $0. The average market capitalization across the [@Biotechnology] industry is $2.19B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNLI’s FA Score shows that 0 FA rating(s) are green whileLGND’s FA Score has 0 green FA rating(s).

  • DNLI’s FA Score: 0 green, 5 red.
  • LGND’s FA Score: 0 green, 5 red.
According to our system of comparison, LGND is a better buy in the long-term than DNLI.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNLI’s TA Score shows that 5 TA indicator(s) are bullish while LGND’s TA Score has 3 bullish TA indicator(s).

  • DNLI’s TA Score: 5 bullish, 3 bearish.
  • LGND’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, DNLI is a better buy in the short-term than LGND.

Price Growth

DNLI (@Biotechnology) experienced а -12.96% price change this week, while LGND (@Biotechnology) price change was -4.44% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -4.95%. For the same industry, the average monthly price growth was -7.12%, and the average quarterly price growth was -11.69%.

Reported Earning Dates

DNLI is expected to report earnings on May 13, 2025.

LGND is expected to report earnings on Apr 30, 2025.

Industries' Descriptions

@Biotechnology (-4.95% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
LGND($2.02B) has a higher market cap than DNLI($1.79B). LGND YTD gains are higher at: -2.175 vs. DNLI (-39.696). LGND has higher annual earnings (EBITDA): 40.8M vs. DNLI (-492.89M). DNLI has more cash in the bank: 832M vs. LGND (256M). LGND has less debt than DNLI: LGND (7.11M) vs DNLI (48.7M). LGND has higher revenues than DNLI: LGND (167M) vs DNLI (0).
DNLILGNDDNLI / LGND
Capitalization1.79B2.02B88%
EBITDA-492.89M40.8M-1,208%
Gain YTD-39.696-2.1751,825%
P/E RatioN/A46.19-
Revenue0167M-
Total Cash832M256M325%
Total Debt48.7M7.11M685%
FUNDAMENTALS RATINGS
DNLI vs LGND: Fundamental Ratings
DNLI
LGND
OUTLOOK RATING
1..100
6875
VALUATION
overvalued / fair valued / undervalued
1..100
94
Overvalued
78
Overvalued
PROFIT vs RISK RATING
1..100
10061
SMR RATING
1..100
9591
PRICE GROWTH RATING
1..100
9054
P/E GROWTH RATING
1..100
9889
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

LGND's Valuation (78) in the Biotechnology industry is in the same range as DNLI (94). This means that LGND’s stock grew similarly to DNLI’s over the last 12 months.

LGND's Profit vs Risk Rating (61) in the Biotechnology industry is somewhat better than the same rating for DNLI (100). This means that LGND’s stock grew somewhat faster than DNLI’s over the last 12 months.

LGND's SMR Rating (91) in the Biotechnology industry is in the same range as DNLI (95). This means that LGND’s stock grew similarly to DNLI’s over the last 12 months.

LGND's Price Growth Rating (54) in the Biotechnology industry is somewhat better than the same rating for DNLI (90). This means that LGND’s stock grew somewhat faster than DNLI’s over the last 12 months.

LGND's P/E Growth Rating (89) in the Biotechnology industry is in the same range as DNLI (98). This means that LGND’s stock grew similarly to DNLI’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNLILGND
RSI
ODDS (%)
Bullish Trend 2 days ago
77%
N/A
Stochastic
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
70%
Momentum
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
76%
MACD
ODDS (%)
Bullish Trend 2 days ago
80%
Bearish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
82%
Bearish Trend 2 days ago
74%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
70%
Advances
ODDS (%)
Bullish Trend 6 days ago
79%
Bullish Trend 14 days ago
75%
Declines
ODDS (%)
Bearish Trend 2 days ago
79%
Bearish Trend 2 days ago
74%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
69%
Aroon
ODDS (%)
Bearish Trend 2 days ago
83%
N/A
View a ticker or compare two or three
Ad is loading...
DNLI
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
LGND
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
BGEIX16.62N/A
N/A
American Century Global Gold Inv
ALPCX10.57N/A
N/A
American Century Focused Lg Cap Val C
OIERX24.52N/A
N/A
JPMorgan Equity Income R5
ISPVX18.64N/A
N/A
Macquarie Smid Cap Core Fund R6
LFGQX30.88N/A
N/A
Lord Abbett Focused Growth R3

DNLI and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNLI has been loosely correlated with BEAM. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if DNLI jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNLI
1D Price
Change %
DNLI100%
-9.60%
BEAM - DNLI
57%
Loosely correlated
-9.70%
ARWR - DNLI
56%
Loosely correlated
-4.20%
RCKT - DNLI
54%
Loosely correlated
-12.89%
NTLA - DNLI
54%
Loosely correlated
-6.40%
RGNX - DNLI
53%
Loosely correlated
-5.45%
More